Pravachol

[Pravastatin]

c Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assess-ment in people with 0-1 risk factor is not necessary.
After the LDL-C goal has been achieved, if the TG is still 200 mg/ dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/ dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is 130 mg/ dL (see NCEP Treatment Guidelines, above).
Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, PRAVACHOL (pravastatin sodium) is not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/ dL) LDL-C (mg/ dL)
Acceptable <170 <110 Borderline 170-199 110-129

High 200 130

DOSAGE AND ADMINISTRATION

Text Continues Below

---

The patient should be placed on a standard cholesterol-lowering diet before receiving PRAVACHOL and should continue on this diet during treatment with PRAVACHOL (see NCEP Treatment Guidelines for details on dietary therapy).

PRAVACHOL can be administered orally as a single dose at any time of the day, with or without food. Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patient's response to therapy and established treatment guidelines.

Adult Patients

The recommended starting dose is 40 mg once daily. If a daily dose of 40 mg does not achieve desired cholesterol levels, 80 mg once daily is recommended. In patients with a history of sig-nificant renal or hepatic dysfunction, a starting dose of 10 mg daily is recommended.

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>